United States· US:71288-039_b9951406-492b-4420-89cc-24fd655824b3
Xenleta
A lefamulin product containing lefamulin acetate, registered in United States by Meitheal Pharmaceuticals Inc.. The same ATC class is registered in 9 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lefamulin is registered in 9 of 19 countries.
Countries holding a registration under ATC J01XX12 (lefamulin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Lefamulin · ATC J01XX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LEFAMULIN ACETATE
- Manufacturer
- Meitheal Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- J01XX12
- ATC class
- Lefamulin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1171288-039-16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
362 interactions on record for lefamulin.
Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lefamulin · interactions on record
362 records
- 133 severe
- 227 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lefamulin in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumXenleta 150 mgVenipharm
- CzechiaXENLETAVENIPHARM S.A.S, Saint Cloud
- FinlandXenletaVenipharm
- IrelandXenleta 150 mg concentrate for solution for infusionNabriva Therapeutics Ireland Designated Activity Company
- IcelandXenletaVENIPHARM
- NetherlandsXenleta 150 mg concentraat en oplosmiddel voor oplossing voor infusieVenipharm
- PolandXenletaNabriva Therapeutics Ireland DAC
- SwedenXenleta 150 mg Koncentrat och vätska till infusionsvätska, lösningVENIPHARM
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xenleta
- Liechtenstein · Xenleta
- Norway · Xenleta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a990c8e6-141a-4158-b338-9831a2d5fa77 GET /v1/drugs/a990c8e6-141a-4158-b338-9831a2d5fa77?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "150",
"substance": "LEFAMULIN ACETATE",
"productndc": "71288-039",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/15mL",
"application_number": "NDA211673",
"marketing_category": "NDA"
}See everything about lefamulin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.